Earnings Call · Q4 FY2023·2024-02-27

Q4 23EPS +6.98%·Rev n/aQ3 23EPS +11.36%·Rev n/aQ2 23EPS +13.64%·Rev n/aQ1 23EPS +10.87%·Rev n/a⚠ consensus missing

Fulcrum Therapeutics, Inc. FULC

Alex Sapir — Chief Executive Officer

Alan Musso — Chief Financial Officer

+4.6%1d on move date+4.4% vs SPY3d+4.9%5d+16.4%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more FULC calls or request research access.

More FULC calls Browse calls Request research access